OpenEye Scientific and Sygnature Discovery announced the adoption of OpenEye's Orion™ platform to power Sygnature's computational efforts in molecular design drug discovery solutions.
On behalf of pharmaceutical and biotechnology companies globally, all of Sygnature Discovery's Computer-Aided Drug Design team will benefit from the Orion platform's large-scale capabilities: virtual high-throughput screening of billions of molecules, molecular dynamics simulations including binding free energy calculations, and quantum mechanics calculations.
"Our mission at Sygnature is quite simple: to enable success for our customers through world class science, and to help bring life-changing therapeutics through the challenging drug discovery process in order to help patients get the best medicines possible," said Dr. Simon Hirst, CEO and Founder of Sygnature Discovery. "That means employing the best technologies available to support our scientists in that quest, and we are very excited to see how the Orion platform will power more efficiency and new breakthroughs in our projects."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Sygnature's use of the Orion platform provides cloud-based molecular and data visualization and analytics as well as facile access to the latest scientific methods, making it possible for Sygnature to unify and operate modeling tasks for the first time without leaving the cloud.
"Sygnature Discovery is using Orion exactly as we conceived: as a molecular design ecosystem of data visualization, communication and workflow tools in a robust, scalable cloud environment," said Dr. Anthony Nicholls, CEO of OpenEye Scientific. "It is really gratifying to see Sygnature helping its clients identify more hits and optimize more leads using Orion's industry-leading technology infrastructure and scientific methods."